OTCM
SDZXF
Market cap17bUSD
Apr 03, Last price
41.36USD
1D
2.75%
IPO
48.92%
Name
Sandoz Group AG
Chart & Performance
P/E
—
P/S
1.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
10.38b
+4.06%
Net income
0k
-100.00%
CFO
656m
+81.22%
Earnings
Aug 07, 2025
Profile
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 10,384,000 4.06% | 9,979,000 12.64% | 8,859,184 0.74% | ||
Cost of revenue | 8,823,000 | 8,730,000 | 5,502,153 | ||
Unusual Expense (Income) | |||||
NOPBT | 1,561,000 | 1,249,000 | 3,357,031 | ||
NOPBT Margin | 15.03% | 12.52% | 37.89% | ||
Operating Taxes | (12,000) | 50,000 | 361 | ||
Tax Rate | 4.00% | 0.00% | |||
NOPAT | 1,573,000 | 1,199,000 | 3,357,031 | ||
Net income | 77,000 -336,918.16% | (23) -100.00% | |||
Dividends | (215,000) | ||||
Dividend yield | |||||
Proceeds from repurchase of equity | (12,000) | ||||
BB yield | |||||
| Debt | |||||
Debt current | 187,000 | 323,000 | 199,843 | ||
Long-term debt | 5,000,000 | 4,539,000 | 109,174 | ||
Deferred revenue | 81,418 | ||||
Other long-term liabilities | 511,000 | 596,000 | 443,171 | ||
Net debt | 3,996,000 | 3,730,275 | 288,562 | ||
| Cash flow | |||||
Cash from operating activities | 656,000 | 362,000 | 1,168,045 | ||
CAPEX | (404,000) | (567,948) | (407,813) | ||
Cash from investing activities | (740,000) | (614,000) | (410,678) | ||
Cash from financing activities | 242,000 | 1,242,000 | (734,445) | ||
FCF | 1,870,424 | 5,201,508 | (4,679,927) | ||
| Balance | |||||
Cash | 1,191,000 | 1,109,000 | 100 | ||
Long term investments | 22,725 | 20,354 | |||
Excess cash | 671,800 | 632,775 | |||
Stockholders' equity | 26,000 | 7,287,524 | (147,955) | ||
Invested Capital | 13,502,000 | 13,170,225 | (130,453) | ||
ROIC | 11.80% | 18.39% | 84.39% | ||
ROCE | 11.32% | 8.89% | |||
| EV | |||||
Common stock shares outstanding | 432,200 | 431,200 | 431,000 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | 2,063,000 | 1,774,000 | 3,794,451 | ||
EV/EBITDA | |||||
Interest | 251,000 | 202,000 | 84,046 | ||
Interest/NOPBT | 16.08% | 16.17% | 2.50% | ||